The UT Southwestern Physician Scientist Oncology Training Program will provide fellows and residents who have finished their clinical training in oncology the opportunity and protected time to develop the technical and intellectual skills for a successful laboratory based oncology research program. The program will accomplish this by providing highly individualized mentorship, the opportunity to train in the research laboratories o one of our internationally renowned faculty and up to three years of stipend support during the years of their research training. Specifically, the goals of the program are to support physicians who have finished their subspecialty clinical training in oncology and train them in lab-based translational oncology research, by providing (a) training in the laboratory skills necessary to investigate the pathogenesis and biology of cancer, (b) a rigorous mentoring and didactic program in the biology of cancer, biostatistics, ethics, and regulatory issues, (c) and training in the investigation of basic cancer questions which are clinically relevant, and in the translation o clinical observations into hypothesis based laboratory questions. Trainees will be mentored primarily by scientists who participate in one of the four programs in the Cancer Center, but will also have secondary, clinical research resource faculty mentors to ensure that the trainee develops the clinical skills and expertise necessary to succeed in a multi- disciplinary approach to the study of clinically relevant cancer questions. 22 laboratory mentors representing 12 different Departments and Centers are committed to this program, as are 15 clinical resource mentors. A Steering Committee consisting of 7 senior physician and scientist leaders in the Cancer Center will provide oversight and direction, and administrative support will be provided by the Cancer Center.

Public Health Relevance

The physician scientist workforce is shrinking, portending decreases in new discoveries needed to conquer such lethal diseases as cancer. The goal of this Oncology Physician Scientist T32 renewal application program is to produce successful, highly qualified, physician scientists who are committed to an academic career in patient-related basic and/or translational oncology research; who will be capable of leading and managing independent research programs; and who will be able to interact with basic, clinical, and translational researchers in collaborative team settings. This application describes a flexible career development program with a multi- disciplinary approach to the conduct and design of lab-based hypothesis-driven cancer questions, under the direction of a primary, lab-based mentor who participates in one of four major Cancer Center Programs.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Lim, Susan E
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas Sw Medical Center Dallas
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Woldu, Solomon L; Hutchinson, Ryan C; Singla, Nirmish et al. (2018) Prospective Monitoring and Adapting Strategies for Prevention of Infection Following Transrectal Prostate Procedures. Urol Pract 5:124-131
Zhang, Yuqing; Kirane, Amanda; Huang, Huocong et al. (2018) Cyclooxygenase-2 inhibition potentiates the efficacy of vascular endothelial growth factor blockade and promotes an immune stimulatory microenvironment in preclinical models of pancreatic cancer. Mol Cancer Res :
Woldu, Solomon L; Bagrodia, Aditya (2018) Update on epidemiologic considerations and treatment trends in testicular cancer. Curr Opin Urol 28:440-447
Woldu, Solomon L; Ci, Bo; Hutchinson, Ryan C et al. (2018) Usage and survival implications of surgical staging of inguinal lymph nodes in intermediate- to high-risk, clinical localized penile cancer: A propensity-score matched analysis. Urol Oncol 36:159.e7-159.e17
Lotan, Yair; Woldu, Solomon L; Sanli, Oner et al. (2018) Modelling cost-effectiveness of a biomarker-based approach to neoadjuvant chemotherapy for muscle-invasive bladder cancer. BJU Int 122:434-440
Woldu, Solomon L; Matulay, Justin T; Clinton, Timothy N et al. (2018) Impact of hospital case volume on testicular cancer outcomes and practice patterns. Urol Oncol 36:14.e7-14.e15
Clinton, Timothy N; Bagrodia, Aditya; Lotan, Yair et al. (2017) Tissue-based biomarkers in prostate cancer. Expert Rev Precis Med Drug Dev 2:249-260
Yin, Yi; Li, Rui; Xu, Kangling et al. (2017) Androgen Receptor Variants Mediate DNA Repair after Prostate Cancer Irradiation. Cancer Res 77:4745-4754
Patil, Rohit V; Woldu, Solomon L; Lucas, Elena et al. (2017) Metastatic Melanoma to the Bladder: Case Report and Review of the Literature. Urol Case Rep 11:33-36
Aydin, Ahmet Murat; Woldu, Solomon L; Hutchinson, Ryan C et al. (2017) Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer. Onco Targets Ther 10:1487-1502

Showing the most recent 10 out of 24 publications